Oncology trials - The elephant in the room

Nature Reviews Clinical Oncology

Volumn 9, Issue 4, 2012, Pages 185-186

  Kirk, Rebecca ^a   Hutchinson, Lisa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; LYMPHOMA; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84859388678     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.33     Document Type: Editorial

References (10)

1. Arrowsmith, J. Trial watch: Phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10, 87 (2011).
2. Rinaldi, F., George, E. & Adler, A. I. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. Lancet Oncol. 13, 233-234 (2012).
3. DeVita, V.T. Jr The clinical trials system is broken. Nat. Clin. Pract. Oncol. 5, 683 (2008).
4. Chabner, B. A. & Roberts T. G. Jr. Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65-72 (2005).
5. Yap, T. A., Sandhu, S. K., Workman, P. & de Bono, J. S. Opinion: Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514-523 (2010).
6. Rubin, E. H. & Gilliland, D. G. Drug development and clinical trials-the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9, 215-222 (2012).
7. Jonsson, B. & Bergh, J. Opinion: Hurdles in anticancer drug development from a regulatory perspective. Nat. Rev. Clin. Oncol. 9, 236-243 (2012).
8. Institut National du Cancer. Les plateformes hospitalières de génétique moléculaire [online, French], http://www.e-cancer.fr/soins/plates-formes-hospitalieres-de-genetique- moleculaire (2012).
9. Dal-Ré, R. et al. (2011) Disclosure of investigators' recruitment performance in multicenter clinical trials: a further step for research transparency. PLoS Med. 8, e1001149 (2011).
10. Sharma, M. R. & Schilsky, R. L. Role of randomized phase III trials in an era of effective targeted therapies. Nat. Rev. Clin. Oncol. 9, 208-214 (2012).